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Abstract
Background: Synchronous multifocal tumours are commonly observed in urothelial carcinomas of the bladder. The
origin of these physically independent tumours has been proposed to occur by either intraluminal migration
(clonal) or spontaneous transformation of multiple cells by carcinogens (field effect). It is unclear which model is
correct, with several studies supporting both hypotheses. A potential cause of this uncertainty may be the small
number of genetic mutations previously used to quantify the relationship between these tumours.
Methods: To better understand the genetic lineage of these tumours we conducted exome sequencing of
synchronous multifocal pTa urothelial bladder cancers at a high depth, using multiple samples from three patients.
Results: Phylogenetic analysis of high confidence single nucleotide variants (SNV) demonstrated that the
sequenced multifocal bladder cancers arose from a clonal origin in all three patients (bootstrap value 100 %).
Interestingly, in two patients the most common type of tumour-associated SNVs were cytosine mutations of TpC*
dinucleotides (Fisher’s exact test p < 10−41), likely caused by APOBEC-mediated deamination. Incorporating these
results into our clonal model, we found that TpC* type mutations occurred 2-5× more often among SNVs on the
ancestral branches than in the more recent private branches (p < 10−4) suggesting that TpC* mutations largely
occurred early in the development of the tumour.
Conclusions: These results demonstrate that synchronous multifocal bladder cancers frequently arise from a clonal
origin. Our data also suggests that APOBEC-mediated mutations occur early in the development of the tumour and
may be a driver of tumourigenesis in non-muscle invasive urothelial bladder cancer.
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Background
Synchronous multifocal tumours are present in ~30 % of
all non-muscle invasive urothelial carcinomas of the
bladder. Two competing theories have been proposed to
describe how these physically separated independent
tumours arise. The clonal hypothesis suggests that multi-
focal tumours are formed by intraluminal or intraepithelial
migration of cells that are shed from a founder tumour. In
contrast, the field hypothesis proposes that a large area of
cells is first partially transformed by a carcinogen and then
subsequently acquires additional mutations that induce
neoplastic transformation. As cancer occurs by the se-
quential accumulation of transformative mutations, each
model would produce a different genetic signature
(Fig. 1a). Various studies investigating the origin of multi-
focal bladder cancer have produced conflicting reports.
Classic work characterizing the X-chromosomal inactiva-
tion patterns in female patients [1] and microsatellite loss
of heterozygosity (LOH) [2] clearly demonstrated a clonal
origin. Further, tumours analysed by array-based compara-
tive genomic hybridization also showed monoclonality [3].
However, in a study of 21 bladder cancer patients, ~30 %
of patients demonstrated significant LOH allelic
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differences among tumours with >40 % of patients
showing some allelic variance, suggesting that these tu-
mours arose from a field effect [4]. Additional research
with microdissected bladder tumour samples also demon-
strated similar results in accordance with a field effect
hypothesis [5, 6]. Interestingly, in a recent study of meta-
chronous multifocal tumours, the authors clearly demon-
strated that these arose from a clonal origin [7].
A potential cause of this variability could be attributed
to the small number of genetic mutations used to quantify
the relationship of the tumours. Given the intrinsic gen-
etic instability of cancer, the mutational markers selected
to quantify the relationship between these tumours could
drastically alter their predicted molecular origins. We
therefore hypothesized that the thousands of unbiased
genetic markers generated through next-generation se-
quencing would be ideally suited to determine the origin
of synchronous multifocal bladder cancer.
Methods
Ethics and consent
Ethical approval was obtained for this study from the Koç
University Institutional Review Board (2012.017.IRB2.007)
in accordance with the Declaration of Helsinki. Written
consent to participate in this study was obtained from all
patients.
Clinical sample collection
Synchronous multifocal tumours were obtained from
male patients (62–72 years old) with pTA papillary
urothelial carcinoma. During transurethral resection, all
macroscopically visible tumours were resected and a
sample from the normal mucosa was taken for study
purposes. Normal mucosa sample was located equidis-
tantly with respect to the tumoural foci. As a result, a
total of four samples (three neoplastic, one normal) were
collected from each patient.
Samples were washed in saline solution and then snap
frozen in liquid nitrogen within 10 min of the resection.
Molecular biology methodology
Genomic DNA was isolated from samples following
mechanical shearing using the Qiagen QIAmp DNA kit as
per the manufacturer instructions. Illumina adaptor se-
quences were added to sheared and blunted gDNA by TA
ligation. Exomic sequences were captured with Agilent
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Fig. 1 SNV distribution and phylogeny of tumours. a Hypothetical phylogenies with the field effect and monoclonal origin hypotheses.
b Number of SNVs with respect to occurrence among samples. Tumour 1 Apex, Tumour 1 Base, Tumour 2 Base/Apex, Normal private: SNVs
only in that sample. As there are only 3 normal private mutations their bar is too small to be visually noticeable. All samples shared: SNVs in all 4
samples, representing the individual genotype. Other: SNVs in the normal mucosa sample and in one or in two tumour samples. All tumours
shared: SNVs in all 3 tumour samples but not in normal mucosa. Other tumour-associated: SNVs in found in one or two but not all tumours and
not in normal mucosa. c Neighbour-joining tree of the 4 samples and the human reference genome based on 1628–1733 high-confidence SNVs.
Bootstrap support for each internal node is indicated. d Proportion of functional SNVs among all SNVs shared among all 4 samples (n = 143–182),
and SNVs shared among all 3 tumours (n = 116–152). ***: Fisher’s exact test p < 0.001
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SureSelect v5 and sequenced on an Illumina HiSeq 2000
with 100bp paired end reads at 100× coverage by Centril-
lion BioScience as a contract service.
Sequence alignment
We aligned the resulting sequencing data (Additional file 1:
Table S1) to the reference human genome (hg19/NCBI
GRCh37) using the BWA aligner (version 0.7.10) using
the “mem” algorithm with default options and paired-
end mode [8]. Following this, to correct for mapping
biases, we used the GATK tool for realigning indel-
containing reads [9]. GATK UnifiedGenotyper in multi-
sample mode was used to generate SNV and indel callsets
by pooling read data from the four samples of a patient.
The Variant Quality Score Recalibration filter was used
from the GATK resource bundle version 2.5 to help
minimize false positives. Since this project is focused on
cancer- and tissue- specific variants, we removed any SNV
or indel prediction that is represented in dbSNP version
138. Therefore, common SNPs were not included in the
genetic analysis. In our final SNV dataset we only included
SNVs and indels where the genotype was reliably detected
(passed the GATK quality filter) and was supported by ≥4
reads in all four samples. This procedure was repeated in-
dependently for each patient.
Population genetics analysis
Downstream bioinformatic analysis was conducted using
R and Python programming languages. The SNV data
was converted into binary form, with heterozygous or
homozygous non-reference alleles called “1”, and homo-
zygous reference alleles called “0”. The same approach
was applied to the indel data. We added the reference
genome (“0” s at all positions) to these datasets. The bin-
ary datasets were used to calculate Euclidean distance
matrices among samples using the R “dist” function. We
then constructed phylogenetic trees using the R “ape” pack-
age’s [10] “bionj” algorithm – a variant of the neighbor-
joining algorithm suggested to perform well when branch
lengths are heterogeneous, as in our case [11]. The “refer-
ence genome” was used to root the tree. Using the more
simple Unweighted Pair Group Method with Arithmetic
Mean algorithm produced qualitatively identical results
(data not shown). We performed 10,000 bootstraps using
the “boots.phylo” function of the R “ape” package.
Analysis of indels
We also identified 2130–2555 indels in the three pa-
tients (Additional file 1: Table S1) using the GATK ana-
lysis procedure described above. We repeated the same
phylogenetic analysis as above using indels, but the
phylogenetic relationships could not be resolved (low
bootstrap support) (Additional file 2: Figure S1). Observ-
ing a strong phylogenetic signal using SNVs, but not
using indels can be explained by homoplasies (conver-
gent evolution), but more likely, high technical noise in
indel calls in exome sequencing at this coverage. We did
not include indels in further analysis.
Functional analysis
We used the “snpEff” software [12] to annotate SNVs
and indels according to their impact on protein struc-
ture. All mutations predicted to have low, moderate or
high impact on protein sequence (e.g. loss of splice sites,
non-synonymous substitutions, stop-codon insertions)
were considered “functional.” We compared ratios of
functional vs. non-functional mutations between SNV
sets (e.g. those shared among all samples vs. those
shared only among the 3 tumour samples) with the
Fisher’s exact test using the R “fisher.test” function.
Mutation type analysis
We classified SNVs based on the dinucleotide sequence
context following Lawrence et al. [13], where we re-
corded the nucleotide preceding an SNV using the hu-
man reference genome (hg19). To simplify the analysis,
following Nordentoft et al. [7] we only considered A and
C positions in the reference genome and the preceding
nucleotide, on each strand, and made a list of all SNVs
in dinucleotide context. We compared the frequencies
of TpC* vs. non-TpC* mutations between SNV sets (e.g.
SNVs shared among all samples, SNVs shared only
among the 3 tumour samples, and SNVs private to tu-
mours) with the Fisher’s exact test. We similarly com-
pared dinucleotide frequencies taking into account the
resulting mutation, as well as trinucleotide frequencies
(Additional file 3: Table S3).
Candidate driver gene analysis
We identified a series of potential driver mutations from
those genes frequently mutated in bladder cancer in the
COSMIC [14] and ATLAS [15] databases (as of October
1st, 2014). This yielded 94 candidate driver mutations.
We then checked for overlap between this list and genes
containing SNVs that are both functional (based on the
“snpEff” software; see above) and are mutated in at least
one tumour sample.
Results
Exome sequencing of synchronous multifocal tumours
Synchronous multifocal tumour samples were surgically
removed from the bladder during transurethral resec-
tion. Ethical approval and patient consent were obtained
for all sample collections. Material from patients was
only sampled if the tumours were physically separated
(>1cm). Resected material from three patients with a
low/high grade, pTa, urothelial carcinoma with very little
stromal cell contamination was used for further analysis.
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In each patient, genomic DNA was isolated from the
base and apex of a single tumour, the base of a second
tumour and the normal bladder mucosa (four samples/
patient). Multiple samples were taken from a single
tumour to determine the intratumoural mutation het-
erogeneity. The exome regions of gDNA were enriched
and sequenced with paired-end Illumina sequencing at
100× coverage. High-depth coverage was used to in-
crease confidence in mutation calling. The resulting se-
quences (51–66 million reads/sample) were aligned to
the human reference genome (GRCH37) with 94 % of
the reads successfully mapping (Additional file 1: Table
S1). By using strict filtering criteria (≥4 reads in each
sample, see Material and Methods), between 1628–1733
single nucleotide variants (SNV) were identified in each
patient.
In the first two patients, approximately half (52–61 %)
of these SNVs were shared among all samples including
the normal mucosa. These SNVs were assumed to repre-
sent the individual’s unique genotype, i.e. germline vari-
ants. Almost all of the remaining SNVs (33–45 %) were
observed in at least one tumour sample but not in the
normal mucosa. These somatic mutations were therefore
defined as “tumour-associated SNVs” (n = 564–734). In
these patients, the majority of the tumour-associated
SNVs were shared among all three tumour samples (58–
84 %), with only 0.6–5 % (n = 11–80 SNVs) private to
each tumour (Fig. 1b). In contrast, in the third patient,
80 % of SNVs were shared among all samples, while only
15 % of the SNVs were tumour-associated, and only 2 %
of these were shared among all tumour samples
(Additional file 4: Figure S2). Therefore, in the third pa-
tient, the normal sample’s genetic profile appears very
similar to those of the tumour samples.
We then built phylogenetic trees based on the SNVs
detected in each patient, and bootstrapped over these
mutations. The trees for the first two patients clearly
demonstrated that the tumour samples are monophyletic
(of clonal origin) with significantly similar genetic signa-
tures to each other compared to the normal tissue
(Fig. 1c, bootstrap value 100 %). Notably, the bootstrap
test ensures that the phylogenetic trees are robust to any
random sequencing errors. In both trees, the tumour
branches were markedly longer than the normal mucosa
branch, indicating an excess of mutation accumulation
in the tumour lineages. In contrast, the “normal” sample
clustered together with the other tumour samples with
high confidence in the third patient’s phylogenetic tree
(Additional file 5: Figure S3). In this patient, neither
tumour branch was longer than the “normal” sample
branch, in contrast to what was observed in the other
two patients. We therefore concluded that the “normal”
sample from the third patient contained contaminating
neoplastic material. Supporting this theory, the “normal”
sample was found to have functional mutations in many
classical bladder cancer tumour suppressors (Additional
file 6: Table S2). Meanwhile, we noted that this patient’s
first tumour’s apex and second tumour’s base clustered
together (Additional file 5: Figure S3), to the exclusion
of the first tumour’s base. The second tumour is therefore
a phylogenetic sub-branch of the first tumour. This can
only be explained by a monoclonal origin of the two tu-
mours, rather than the field effect hypothesis. Together,
these results strongly support a clonal origin for all of the
collected synchronous multifocal tumours.
We then investigated the functionality of tumour-
associated SNVs in the first two patients, relative to
SNVs representing the individual’s genotype. Classifying
all 1628–1733 SNVs according to their impact on pro-
tein sequence revealed that 350–354 (20–22 %) of these
mutations were potentially functional, i.e. altered protein
sequence or splicing pattern. Such functional mutations
were about 1.8–2.3 times more common among SNVs
shared among tumours than those representing the indi-
vidual’s genotype (Fig. 1d, Fisher’s exact test p < 10−5).
APOBEC mutations in multifocal tumours
A recent study observed that TpC* mutations (where a
C preceded by a T is mutated) occur at a higher fre-
quency in bladder, cervical and head-and-neck cancers
[16]. This pattern was proposed to be caused by over-
activation of APOBEC family single stranded RNA/DNA
editing enzymes; APOBECs can cause widespread
cytosine deamination, possibly in response to retroviral
infection [17]. We therefore asked whether TpC* substi-
tutions might also accumulate at high rate in the tu-
mours sampled. Indeed, we found higher TpC* substitution
frequencies, particularly TpC*- > TpT*/TpG*, relative to
non-tumour associated mutations in two of first two
patients (Fig. 2a, Additional file 3: Table S3 and Additional
file 7: Table S4). Compared to the SNVs representing the
individual’s genotype (n = 842–1059), the SNVs shared
among all tumours (n = 428–473) had a 6–6.3 fold
higher proportion of TpC* mutations (Fisher’s exact
test p < 10−41). Furthermore, TpC* mutations shared
among tumours were most frequent in the context of
TpC*pA, consistent with the APOBEC3B mutational
signature [18] (Additional file 3: Table S3). Given that
these tumours arise from a common origin, we can
roughly assess when these TpC* mutations occurred
based on the distribution of this particular mutation
within the phylogeny. With this model, we found that
in both patients, TpC* mutations were 2.5–4.6 times
more common along the ancestral tumour branch
(SNVs shared among tumour samples, or “trunk” [19])
relative to more recent branches (SNVs private to each
tumour) (p-value < 10−4, Additional file 8: Table S5).
This data suggests that APOBEC-mediated mutations
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occurred early in the development of the tumours in
these two patients. Supporting this model, we found
that among missense SNVs in common bladder cancer
“driver” genes, as defined by the COSMIC and ATLAS
databases, approximately half were TpC* mutations
(Additional file 6: Table S2). Meanwhile, in the third
patient, TpC* mutation rate did not show a comparable
elevation (Additional file 9: Figure S4) indicating that
this mutation pattern is not ubiquitous for bladder
cancer.
Discussion
Previous studies characterizing the origins of synchron-
ous multifocal bladder cancer produced conflicting re-
sults, with data supporting both a clonal and field effect.
This potentially could be due to the limited number of
genetic markers used in many of these previous studies.
By analyzing a comprehensive set of markers with ex-
ome sequencing it is possible to overcome this limita-
tion. Sequencing data also provides detailed information
that can indicate the possible mechanisms behind each
tumourigenesis event.
Therefore, in this study we conducted next-generation
sequencing and identified thousands of unique SNVs per
patient. With this data, we were able to utilize conven-
tional population genetic models to determine the
relationship between these multifocal tumours. Our data
clearly demonstrated that these tumours arose from a
clonal origin in all three patients sampled. While one of
the patients appears to have a neoplastic contamination
in its “normal” sample, this patient’s data is still consist-
ent with the monoclonal origin model, as there is con-
siderable overlap in the mutations found across the
patient’s samples. Our finding parallels a recent report
indicating a clonal origin for four metachronous tumour
pairs that were characterized by genome sequencing [7].
Such similarity raises the interesting possibility that
metachronous tumours may reflect synchronous tu-
mours that have been “seeded” but not yet grown at the
time of surgery. Both tumour types appear to arise from
a clonal origin, suggesting a similar origin. However, fur-
ther studies will be needed to characterize this potential
relationship.
Once developed this clonal model can be used to pro-
vide insight into the evolutionary timing of the cancer. If
a mutation happens very early in the development of the
cancer it will be shared with all samples, however a mu-
tation that occurs late will only be found in a single re-
gion or tumour. We applied this concept to study the
timing of TpC* mutation accumulation. Recent work has
demonstrated that this class of mutations occurs by over-
activation of the cytosine deaminase APOBEC3B [16, 17].
This enzyme is believed to be important in the host-
defence of retroviruses and transposons; however large-
Fig. 2 a SNV frequencies in dinucleotide context. Frequencies are compared between SNVs among all SNVs shared among all 4 samples
(n = 842–1059), and SNVs shared among all 3 tumours (n = 428–473). Asterisks indicate which base is mutated; e.g. TpC* stands for TpC- > TpA,
TpC- > TpG, or TpC- > TpT. Inset shows the frequency of substitutions in all tumours at TpC* sites. We only consider A or C mutations in either
strand and their 5’ nucleotides, following [9]. b Proposed development of the bladder cancer lesion from initiation of transformation to migration
of the clonal tumours
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scale cancer genome sequencing studies have demon-
strated that it is also a major mutagenic factor in many
types of cancer [18]. Our results demonstrated that in two
patients, APOBEC-mediated mutations occurred very early
in tumour development and could potentially be important
in the initial neoplastic transformation (Fig. 2b). This is
seen in the high frequency of TpC* mutations in potential
“driver” mutations, including missense TpC* mutations in
well-known genes such as KMTD2 and ATM shared
across all tumours of a patient (Additional file 6: Table
S2). Our result deviates from recent studies reporting
accelerating of APOBEC-mediated mutations in lung
cancer in smokers [19], or constitutive accumulation in
early and late metachronous bladder cancer tumours [7].
This difference may reflect variation in the role of APO-
BEC activity in different cancers. Our finding also suggests
that, as TpC* mutations primarily occur early in the devel-
opment of the cancer, therapeutic targeting of APOBEC3B
may not be suitable in non-muscle invasive bladder
cancer.
Overall this study demonstrates the utility of exome
sequencing and population genetic analysis in character-
izing the molecular evolution of synchronous bladder
cancer tumours.
Conclusions
By using next-generation sequencing to identify a large
number of unique mutations our study clearly demon-
strates that multifocal tumours primarily arise from a
clonal origin. Interestingly our work also suggests that
APOBEC mutations occur relatively early in the devel-
opment of non-muscle invasive bladder cancer.
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